Study finds lung transplant patients not given antifungal preventive drugs have higher risk of death

Credit: CC0 Public Domain

Antifungal preventive medications reduce mortality risk by half in the first year following lung transplantation, according to Mayo Clinic research involving 667 patients who received lung transplants from 2005 to 2018.

The retrospective study, published in the Annals of the American Thoracic Society, is the largest ever to evaluate the effectiveness of preventive drugs in lung transplant recipients who are particularly susceptible to invasive fungal infections. These infections are associated with a nearly threefold increase in mortality for lung transplant recipients.

Mayo Clinic researchers used deidentified administrative claims data from OptumLabs Data Warehouse. The study analyzed data for who underwent single or double lung transplant, or concurrent heart-lung transplant, in the U.S. between Jan. 1, 2005, and Dec. 31, 2018. Of the 667 patients, 385, or 57.8%, received antifungal treatment and 282, or 42.3%, did not. Sixty-five patients died during the study, and all-cause mortality was significantly lower in those patients who received .

"Use of antifungal preventive medications in lung transplant patients is increasingly common, but no studies have established its efficacy," says Kelly Pennington, M.D., the study's first author. "This is the first study to demonstrate a mortality benefit associated with the use of antifungal prophylaxis in lung transplant patients. We still do not know which lung transplant patients receive the most benefit from these medications, and there are other unanswered questions that will require more research." Dr. Pennington is a Mayo Clinic Scholar in the Division of Pulmonary and Critical Care Medicine.

A 2019 Mayo Clinic study found that 90% of U.S. transplant centers routinely prescribe antifungal preventive medications after lung transplant, but no prospective studies have established the benefits of these medications. "In our , the risk of death within the first year posttransplant is about twice as high in patients not receiving antifungal preventive treatment, compared with those receiving treatment," says Dr. Pennington.

Itraconazole and voriconazole were the two most common antifungal preventive medications prescribed in the study. Patients who received antifungal drugs had a lower rate of fungal infections than those who did not, though the difference was not statistically significant.

Protracted use of antifungal drugs can have , including cardiomyopathy, skin cancer and liver dysfunction. Also, antifungal medications are expensive and can interact with other medications. Therefore, the health care team must monitor anti-fungal medications closely.

"Given the variation in practice among transplant centers, the potential for medication side effects, costs and risk of drug interactions, it was imperative to determine whether antifungal preventive medications are beneficial for lung transplant recipients," says Cassie Kennedy, M.D., senior author. "Our finding of a significant reduction in among lung transplant recipients who received antifungal medications is consistent with several prior studies in hematologic malignancies and bone marrow transplant patients."

Dr. Kennedy is a physician in Mayo Clinic's Division of Pulmonary and Critical Care Medicine. None of the authors has a conflict of interest to disclose.

Explore further

Lung transplant patients face elevated lung cancer risk

Provided by Mayo Clinic
Citation: Study finds lung transplant patients not given antifungal preventive drugs have higher risk of death (2020, September 23) retrieved 18 January 2022 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Feedback to editors